This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
5 Top Picks to Tap the Dow and S&P 500's Back-to-Back Rally
by Nalak Das
Stocks have fallen significantly in a short period of time and several of them offer lucrative buying opportunity at this stage.
CytomX & Astellas Collaborate to Develop Novel Cancer Therapy
by Zacks Equity Research
CytomX (CTMX) and Astellas Pharma sign collaboration agreement to develop novel cancer therapy using CytomX's Probody therapeutic technology platform.
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks - March 25, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
5 Unbeatable Dividend Growth Stocks for a Solid Portfolio
by Sweta Killa
Picking stocks that not only pay out dividends but also increase them on a regular basis appears a winning strategy.
Eiger Completes NDA Submission of Progeria Drug Lonafarnib
by Zacks Equity Research
Eiger (EIGR) completes rolling submission of the NDA seeking approval for lonafarnib as a treatment for progeria and progeroid laminopathies, ultra-rare diseases causing accelerated aging in children.
Powerful Proof Anyone Can Invest for an Early Retirement - March 24, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, BHP, CVS Health, T-Mobile US and Anthem
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, BHP, CVS Health, T-Mobile US and Anthem
Top Research Reports for Bristol-Myers, BHP & CVS
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Bristol-Myers Squibb (BMY), BHP Group (BHP) and CVS Health (CVS).
Bristol-Myers Squibb (BMY) Stock Moves -0.8%: What You Should Know
by Zacks Equity Research
Bristol-Myers Squibb (BMY) closed the most recent trading day at $48.40, moving -0.8% from the previous trading session.
How Trading Your Own Retirement Can Fleece Your Financial Future - March 20, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
AVEO Pharmaceuticals (AVEO) Q4 Earnings Beat & Sales Miss
by Zacks Equity Research
Even though AVEO Pharmaceuticals (AVEO) reports narrower-than-estimated loss in the fourth quarter, its revenues miss the mark.
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks - March 17, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Simple Secrets Anyone Can Use to Reach Early Retirement - March 16, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
Pharma Stock Roundup: ABBV, LLY Coronavirus Product Development Efforts, FDA Updates
by Kinjel Shah
Lilly (LLY) signs deal with AbCellera to co-develop antibody therapies to treat COVID-19. AbbVie (ABBV) supports studies evaluating Kaletra for treating COVID-19.
Bristol Myers' Opdivo+Yervoy Combo Gets FDA Nod for HCC
by Zacks Equity Research
Bristol Myers (BMY) gets FDA approval for the Opdivo and Yervoy combination for the treatment of HCC.
The Extreme Risks of Trading Your Own Retirement Assets - March 12, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks - March 11, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Bristol-Myers Empliciti Combo Fails in First-Line Myeloma Study
by Zacks Equity Research
Bristol-Myers' (BMY) Empliciti, Revlimid and dexamethasone combination regimen fails to improve progression free survival in first-line multiple myeloma patients.
Is Amgen (AMGN) Truly One of the Best Biotech Stocks to Own?
by Zacks Equity Research
Amgen (AMGN) boasts a strong biosimilars portfolio, which can drive long-term growth. Amgen is also progressing with its pipeline while regularly pursuing business development deals.
Why Is Bristol-Myers (BMY) Down 10.1% Since Last Earnings Report?
by Zacks Equity Research
Bristol-Myers (BMY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Idera Completes Recruitment in Late-Stage Melanoma Study
by Zacks Equity Research
Idera (IDRA) closes enrollment in the late-stage ILLUMINATE-301 study, evaluating the combo of tilsotolimod plus Yervoy in patients with anti-PD-1 refractory advanced melanoma.
Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?
by Sweta Killa
Smart Beta ETF report for EUSA
Simple Secrets Anyone Can Use to Reach Early Retirement - March 06, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Bristol-Myers Squibb (BMY) Stock Moves -1.59%: What You Should Know
by Zacks Equity Research
Bristol-Myers Squibb (BMY) closed at $60.50 in the latest trading session, marking a -1.59% move from the prior day.